AU2013361053A1 - Transmucosal delivery of glatiramer acetate - Google Patents

Transmucosal delivery of glatiramer acetate Download PDF

Info

Publication number
AU2013361053A1
AU2013361053A1 AU2013361053A AU2013361053A AU2013361053A1 AU 2013361053 A1 AU2013361053 A1 AU 2013361053A1 AU 2013361053 A AU2013361053 A AU 2013361053A AU 2013361053 A AU2013361053 A AU 2013361053A AU 2013361053 A1 AU2013361053 A1 AU 2013361053A1
Authority
AU
Australia
Prior art keywords
percent
present
oral tablet
tablet
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013361053A
Other languages
English (en)
Inventor
Martina BUERGER
Ursula GEISTER
Gerald Huber
Tanja PRIES
Stephan Schweizer
Ralph Stefan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2013361053A1 publication Critical patent/AU2013361053A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013361053A 2012-12-21 2013-12-20 Transmucosal delivery of glatiramer acetate Abandoned AU2013361053A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745226P 2012-12-21 2012-12-21
US61/745,226 2012-12-21
PCT/US2013/077034 WO2014100639A1 (en) 2012-12-21 2013-12-20 Transmucosal delivery of glatiramer acetate

Publications (1)

Publication Number Publication Date
AU2013361053A1 true AU2013361053A1 (en) 2015-07-30

Family

ID=50979257

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013361053A Abandoned AU2013361053A1 (en) 2012-12-21 2013-12-20 Transmucosal delivery of glatiramer acetate

Country Status (15)

Country Link
US (1) US20160193276A1 (enExample)
EP (1) EP2934492A4 (enExample)
JP (1) JP2016503803A (enExample)
KR (1) KR20150111918A (enExample)
CN (1) CN104869983A (enExample)
AU (1) AU2013361053A1 (enExample)
BR (1) BR112015014095A2 (enExample)
CA (1) CA2895359A1 (enExample)
EA (1) EA201591188A1 (enExample)
HK (2) HK1214134A1 (enExample)
IL (1) IL239280A0 (enExample)
MX (1) MX2015007678A (enExample)
SG (1) SG11201504422XA (enExample)
WO (1) WO2014100639A1 (enExample)
ZA (1) ZA201505049B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
CA2851510A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015140790A1 (en) 2014-03-17 2015-09-24 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
CN106924175B (zh) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物
TWI781921B (zh) * 2016-02-12 2022-11-01 日商特一華製藥股份有限公司 乾式造粒物及含有該乾式造粒物之固形製劑以及其製造方法
CN110996983A (zh) 2017-06-26 2020-04-10 巴斯德研究所 清除hiv储库并降低病毒载量的治疗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
IL159715A0 (en) * 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
PT1848415E (pt) * 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
CA2623018A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of telmisartan
BRPI0620578A2 (pt) * 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
PT2201840E (pt) * 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.

Also Published As

Publication number Publication date
WO2014100639A1 (en) 2014-06-26
KR20150111918A (ko) 2015-10-06
CN104869983A (zh) 2015-08-26
BR112015014095A2 (pt) 2017-07-11
JP2016503803A (ja) 2016-02-08
SG11201504422XA (en) 2015-07-30
CA2895359A1 (en) 2014-06-26
HK1214134A1 (zh) 2016-07-22
IL239280A0 (en) 2015-07-30
MX2015007678A (es) 2015-09-07
EP2934492A4 (en) 2016-08-17
EP2934492A1 (en) 2015-10-28
EA201591188A1 (ru) 2016-04-29
ZA201505049B (en) 2016-10-26
US20160193276A1 (en) 2016-07-07
HK1214523A1 (zh) 2016-07-29

Similar Documents

Publication Publication Date Title
US20160193276A1 (en) Transmucosal delivery of glatiramer acetate
EP1173178B1 (en) Composition comprising apomorphine and sildenafil and the use thereof for the treatment of erectile dysfunction
US6376550B1 (en) Pharmaceutical compositions containing tramadol for migraine
AU2007287549B2 (en) Galenic formulations of aliskiren
AU2012250862B2 (en) Rapid dissolve tablet compositions for vaginal administration
AU703242B2 (en) Film coated tablet of paracetamol and domperidone
US20130131098A1 (en) Pharmaceutical formulation of apomorphine for buccal administration
WO2015127558A1 (en) Methods and uses for inducing or facilitating micturition in a patient in need thereof
US20150328277A1 (en) Oral transmucosal delivery of glatiramer acetate
CN1658898B (zh) 包含培哚普利的口腔分散药物组合物
US20040122065A1 (en) Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or buccally
US20060159751A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
PT1807156T (pt) Novas formulações farmacêuticas úteis no tratamento de insónia
KR101697773B1 (ko) 독소필린을 포함하는 변형 방출 조성물
RS57430B1 (sr) Mukoadhezivne bukalne tablete za lečenje orofacijalnog herpesa
WO2014092358A1 (en) Chewable tablet comprising a phosphodiesterase-5 inhibitor
AU2003214326B2 (en) Orally dispersible pharmaceutical piribedil composition
WO2008133952A2 (en) Transmucosal treatment with fentanyl in patients with mucositis
HK1081110B (en) Orally dispersible pharmaceutical piribedil composition

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period